Postoperative Kidney Functions in Geriatric Major Gynecologic-Oncologic Surgery

NCT05308810 | Unknown

• 1 other identifier: E1-22-2381
• Study Type: observational
• Target: 150
• Locations: 1 country
• Sites: 1

Brief Summary

The increasing number of patients who develop perioperative acute kidney injury (AKI) is partly related to the aging population and the increasing number of individuals with chronic comorbidities, particularly those with premorbid chronic kidney disease. Anesthesiologists and surgeons will increasingly have to deal with such patients who are elderly and have comorbidities and require major surgery. The aim of this study was to determine the incidence of postoperative acute kidney injury (primary aim) in patients aged 65 and over who underwent elective major gynecological-oncological surgery under general anesthesia in Ankara City Hospital Gynecology-Oncology Operating Room between January 2020-2022 and were followed up in the PACU in the postoperative period. To investigate risk factors and their results in a retrospective manner in line with the KDIGO criteria (secondary purpose).

Conditions

Geriatrics; Acute Renal Injury; Gynecologic Surgery

Keywords

Geriatrics; Acute Renal Injury; Gynecologic Surgery

Outcome Measures

Primary Outcomes (3)

• the incidence of the patients with AKI STAGE 1

  AKI STAGE 1 : increase Cr ≥ 0.3 mg/dl or increase Cr to 1.5-1.9 times from baseline; or urine volume \< 0.5 ml/kg/h for 6-12 hours AKI STAGE 2 : increase to 2-2.9 times from baseline; or urine volume \< 0.5 ml/kg/h for ≥ 12 hours AKI STAGE 3 : increase Cr to ≥ 3 times from baseline; or increase Cr ≥ 4 mg/dl or initiation of renal replacement therapy or decrease in GFR to \<35mL/min/1.73 m2 or urine volume \< 0.3 ml/kg/h for ≥ 24 hours or Anuria for ≥ 12 hours

  48 hours after surgery

• the incidence of the patients with AKI stage 2

  AKI STAGE 1 : increase Cr ≥ 0.3 mg/dl or increase Cr to 1.5-1.9 times from baseline; or urine volume \< 0.5 ml/kg/h for 6-12 hours AKI STAGE 2 : increase to 2-2.9 times from baseline; or urine volume \< 0.5 ml/kg/h for ≥ 12 hours AKI STAGE 3 : increase Cr to ≥ 3 times from baseline; or increase Cr ≥ 4 mg/dl or initiation of renal replacement therapy or decrease in GFR to \<35mL/min/1.73 m2 or urine volume \< 0.3 ml/kg/h for ≥ 24 hours or Anuria for ≥ 12 hours

  48 hours after surgery

• the incidence of the patients with AKI stage 3

  AKI STAGE 1 : increase Cr ≥ 0.3 mg/dl or increase Cr to 1.5-1.9 times from baseline; or urine volume \< 0.5 ml/kg/h for 6-12 hours AKI STAGE 2 : increase to 2-2.9 times from baseline; or urine volume \< 0.5 ml/kg/h for ≥ 12 hours AKI STAGE 3 : increase Cr to ≥ 3 times from baseline; or increase Cr ≥ 4 mg/dl or initiation of renal replacement therapy or decrease in GFR to \<35mL/min/1.73 m2 or urine volume \< 0.3 ml/kg/h for ≥ 24 hours or Anuria for ≥ 12 hours

  48 hours after surgery

Interventions

Major Gynecologic- oncologic Surgery PROCEDURE

Major Gynecologic-Oncologic surgery between january 2020 - january 2022

Eligibility Criteria

• Age: 65 Years - 90 Years
• Gender Eligibility Details: undergone major abdominal gynecologic oncologic surgery between
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

patients underwent major abdominal gynecologic oncologic surgery and followed in the PACU between January 2021 and January 2022 at Ankara City hospital

You may qualify if:

• patients underwent major abdominal gynecologic oncologic surgery between January 2021 and January 2022
• followed in the PACU

You may not qualify if:

• Patients with inaccessible data and missing data

Sponsors & Collaborators

• Ankara City Hospital Bilkent: lead

Study Sites (1)

Ankara City Hospital

Ankara, 06800, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Acute Kidney Injury

Condition Hierarchy (Ancestors)

Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases

Study Officials

• Aysun Postaci

  Ankara City Hospital Bilkent

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Aysun Postacı

CONTACT

+905323520383; aysunposta@yahoo.com

Namık Özcan

CONTACT

+9005324914531

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal İnvestigator

Study Record Dates

• First Submitted: March 18, 2022
• First Posted: April 4, 2022
• Study Start: April 1, 2022
• Primary Completion: June 1, 2022
• Study Completion: July 1, 2022
• Last Updated: April 4, 2022

Record last verified: 2022-03

Locations

TU (1)